- Investing Ideas
- South Korean Pharmaceuticals & Biotech Healthy potentially undervalued
South Korean Pharmaceuticals & Biotech Healthy potentially undervalued
Results
6
Companies which are potentially undervalued and in an acceptable financial position.
6 companies
Hugel
Market Cap: ₩2.8t
Develops and manufactures biopharmaceuticals in South Korea and internationally.
A145020
₩261,500.00
7D
-2.4%
1Y
-29.7%
Dong-A Socio Holdings
Market Cap: ₩652.9b
Engages in the pharmaceutical business in South Korea.
A000640
₩98,500.00
7D
-0.1%
1Y
1.4%
Dong-A ST
Market Cap: ₩419.1b
Develops, manufactures, and markets pharmaceutical products in South Korea and internationally.
A170900
₩43,600.00
7D
-4.7%
1Y
-3.0%
PharmaResearch
Market Cap: ₩3.5t
Operates as a biopharmaceutical company primarily in South Korea.
A214450
₩339,000.00
7D
2.1%
1Y
-13.0%
Chong Kun Dang Pharmaceutical
Market Cap: ₩1.1t
Manufactures, markets, and sells medicines in South Korea and internationally.
A185750
₩86,100.00
7D
-2.2%
1Y
5.8%
Celltrion
Market Cap: ₩41.5t
A biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products.
A068270
₩197,800.00
7D
-3.0%
1Y
26.7%